Start here if you're new
what it is
Ocugen is a tiny biotech trying to turn eye-disease gene therapy trials into a real business.
how it gets paid
Last year Ocugen made $4M in revenue. COVAXIN commercialization was the main engine at $4.0M, or 100% of sales.
why it's growing
Revenue grew 8.8% last year. $5M of Revenue looks better until you stack it against a n/a operating margin.
what just happened
Revenue hit $5M, but the company still posted a loss and the business remains deeply unprofitable.
At a glance
B balance sheet — gets the job done, barely
25/100 earnings predictability — expect surprises
-$0.23 fy2025 eps est
$2B fy2026 rev est
n/a operating margin
xvary composite: 39/100 — weak
What they do
Ocugen is a tiny biotech trying to turn eye-disease gene therapy trials into a real business.
The pitch is simple. Ocugen has 95 employees and is focused on rare blindness, where small patient pools can still support high pricing if a therapy works. Gene therapy → one-time genetic treatment → so what: if OCU400 works, you may get one asset that matters more than the current $4M revenue base.
How they make money
$4M
annual revenue · their business grew +8.8% last year
COVAXIN commercialization
$4.0M
+8.8%
OCU400
$0.0M
0.0%
OCU410
$0.0M
0.0%
OCU410ST
$0.0M
0.0%
The products that matter
lead retinal gene therapy
OCU400
phase 3 enrollment completed · mar 2026
this is the lead asset in a three-program pipeline, and phase 3 enrollment completed in march 2026. if anything on this page justifies an $813M valuation, it's this program.
lead asset
stargardt disease program
OCU410ST
one of 3 pipeline programs
it matters because Ocugen only has three clinical programs to point to, and this is one of them. with just $4M in trailing revenue, every additional shot on goal carries valuation weight.
pipeline optionality
geographic atrophy program
OCU410
one of 3 pipeline programs
this is the broader-market ambition inside the pipeline, but it is earlier than OCU400. in a company with $193K of quarterly revenue, earlier-stage assets are hope, not cash flow.
earlier stage
Key numbers
$2B
FY2026 revenue est.
That is the gap between the story and the business. You have $2B expected next to just $4M in trailing revenue, a 500x spread.
n/a
operating margin
Prior margin KPI failed sanity check — verify in filings. Operating margin → profit from the core business → so what: for every $1 of sales, Ocugen lost about $14.26 from operations.
$31M
long-term debt
Debt is 4% of capital, which means leverage is not the main problem. The real problem is turning science into revenue before cash runs thin.
95
employees
This is a very small company chasing very large targets. That can create upside, but it also leaves little room for execution mistakes.
Financial health
B
strength
- balance sheet grade B — adequate — nothing special
- risk rank 4 — safer than 20% of stocks
- price stability 5 / 100
- long-term debt $31M (4% of capital)
B — functional but not a standout on the balance sheet.
Total return vs. market
Return history isn't available for OCGN right now.
source: institutional data · return history unavailable
What just happened
missed estimates
Revenue hit $5M, but the company still posted a loss and the business remains deeply unprofitable.
Revenue grew 163% vs. prior year from a tiny base. EPS was -$0.09 in the latest quarter, while the operating margin n/a (verify filings), which tells you growth is not fixing the economics yet.
$5M
revenue
$0.09
eps
n/a
operating margin
the number that mattered
$5M of quarterly revenue looks better until you stack it against a n/a operating margin. Sales exist, but the business model still does not.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk is clinical failure or delay in OCU400. with $4M in trailing revenue and an $813M market cap, this story does not have much room for a miss.
med
OCU400 does not deliver registrational data
Phase 3 enrollment completion is progress, not approval. If the data disappoints or the filing timeline slips, the main pillar under the current valuation weakens immediately.
An $813M stock backed by $4M in trailing revenue has very little fundamental support if the lead program breaks.
med
cash burn forces dilution before the science resolves
Ocugen reported $32.9M of cash and equivalents in q3 2025. Against a $17.7M quarterly loss, the financing window matters almost as much as the trial calendar.
If new capital comes through stock issuance, your ownership gets diluted before the business proves it can generate meaningful revenue.
med
the current revenue base is too small to absorb setbacks
Quarterly revenue was just $193K, and trailing revenue is $4M. That means there is no operating business here large enough to cover development costs if milestones slip.
This exposes most of the story to financing terms, clinical timing, and market sentiment rather than customer demand.
med
the class action adds noise when trust is already fragile
The Portnoy lawsuit alleging securities fraud will not decide whether the pipeline works, but it can absorb management attention and feed volatility.
For a stock with 1.75 beta and 5 / 100 price stability, extra headline risk is not a rounding error.
The combined risk picture is straightforward: almost all of the $813M valuation depends on trial execution and access to fresh capital, while the current business only produces $4M in trailing revenue.
source: institutional data · regulatory filings · risk analysis
Pay attention to
catalyst
OCU400 filing timeline
Phase 3 enrollment completed in march 2026 and management is targeting a 2026 BLA submission. This is the calendar date the whole stock keeps orbiting.
cash
runway versus quarterly losses
$32.9M of cash against a $17.7M quarterly loss does not leave much slack. If losses stay near this pace, financing moves from possibility to near-term necessity.
risk
dilution terms, not just dilution itself
A capital raise is one thing. The price, structure, and timing of that raise are the part that tells you how much damage lands on existing shareholders.
sentiment
whether the story broadens beyond one asset
Ocugen has three clinical programs, but OCU400 still dominates the narrative. If OCU410 or OCU410ST starts carrying more of the conversation, the valuation becomes slightly less one-legged.
Analyst rankings
earnings predictability
25 / 100
Low predictability means the reported numbers can swing around a lot. In human-speak: analysts do not have a stable commercial model to forecast yet.
beta
1.75
Beta measures how hard a stock tends to move versus the market. At 1.75, OCGN has historically moved with extra drama.
source: institutional data
Institutional activity
institutional ownership data for OCGN is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$2
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive